Table 3.

Longitudinal study of two Lyme borreliosis patients, and one non-acute tick-borne disease patient (NA-TBI).

Sample ID	Clinical status	Pathogen	Before EM (after tick bite)	Before treatment—presence of EM	During treatment	Resolution of symptoms
108838	Acute Lyme borreliosis	Borrelia	N/A	3	N/A	0
453742	Acute Lyme borreliosis	Borrelia	3	2	2	N/A
957477	NA-TBI	Ehrlichia	N/A	2a	1	0

In patient 108838 (acute LB), Borrelia-specific peptides are identified in presence of acute symptoms (EM rash) and no peptide is detected after symptom resolution (4 weeks of doxycycline). In patient 453742 (acute LB), Borrelia-specific peptides were identified after tick bite but before development of an EM rash. Peptides were detectable in the pre-treatment stage and in presence of EM rash. Peptide count decreased during early treatment (2 days of doxycycline) when the patient was still symptomatic. In patient 957477 (non-acute tick-borne disease) 2 Ehrlichia peptides were identified in the presence of symptoms before starting treatment, 1 peptide after 14 days of doxycycline and no peptides after 4 weeks of doxycycline.

^aEM rash was not present.